TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square-foot flagship East Coast plant represents a strategic bet on radiopharmaceuticals as the “next revolution” in cancer therapy, addressing severe supply constraints for the rare alpha-particle-emitting isotope that industry leaders believe will transform oncology treatment.
Addressing Critical Supply Bottleneck for Next-Generation Radiopharmaceuticals
The new Philadelphia facility, combined with capacity expansion at TPI’s existing Everett, Washington site, will increase production capacity 20-fold and position the company as the world’s top distributor of Ac-225. The project will create 225 permanent jobs over the next three years, plus approximately 500 construction jobs during the build-out phase, with the facility expected to commence production in 2029.
Scott Claunch, President of TerraPower Isotopes, emphasized the strategic importance:
This new facility is a testament to the demand for actinium-225 as part of the growing industry which is transforming how cancer is treated. Our team is proud to be building a large-scale manufacturing facility in Philadelphia, which will play a pivotal role in expanding global access to this rare isotope.
Scott Claunch/TerraPower Isotopes
The Actinium-225 Opportunity: Alpha Particle Revolution
Actinium-225 is a rare radioactive isotope that emits alpha particles, making it particularly effective at destroying cancer cells with minimal damage to surrounding healthy tissue. While current commercial radiopharmaceuticals like Novartis’ Lutathera and Pluvicto utilize the beta-emitting isotope lutetium-177 (Lu-177), industry experts view Ac-225 as the next breakthrough.
Alpha particles deliver significantly higher energy over shorter distances compared to beta particles, potentially enabling more potent tumor cell killing while sparing healthy tissue. However, Ac-225 requires a completely different production route than lutetium, creating supply chain challenges that TPI’s investment aims to solve.
Strategic Site Selection: Philadelphia’s Life Sciences Ecosystem
After evaluating more than 350 potential locations, TPI selected the Bellwether District for its proximity to key infrastructure and Philadelphia’s robust life sciences ecosystem. The site is a 1,300-acre industrial campus located less than three miles from Center City, Philadelphia International Airport, I-95, and I-76.
Philadelphia is emerging as a powerhouse for radiopharmaceutical innovation, with the region home to globally recognized medical institutions and four National Cancer Institute-designated cancer centers. JLL noted that the city offers unique advantages for nuclear medicine manufacturing and research.
The Commonwealth of Pennsylvania is investing $10 million in the project, including a $7 million grant through the Pennsylvania Strategic Investments to Enhance Sites (PA SITES) Program and a $3 million Pennsylvania First grant. TPI is also eligible for Manufacturing Tax Credit and Qualified Manufacturing and Innovation Reinvestment Deduction programs.
TerraPower’s Proprietary Production Technology
TPI produces Ac-225 derived from legacy U.S. nuclear material, a unique production approach that differentiates the company from competitors using cyclotron or reactor-based methods. The company’s technology platform enables scalable, consistent production of the isotope.
Chris Levesque, President and CEO of TerraPower, stated:
This facility will help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments.
Chris Levesque/TerraPower Isotopes
Radiopharmaceutical Market Context and Partnerships
The radiopharmaceutical sector has seen a surge of investments as pharmaceutical companies and suppliers race to capitalize on growing clinical evidence. Novartis, the market leader, outlined two new radiopharmaceutical manufacturing facilities in Florida and Texas in February 2026 as part of its broader $23 billion U.S. investment53. With these additions, Novartis will operate five radiopharmaceutical manufacturing sites in the U.S.
TPI has secured multiple strategic supply partnerships:
- PanTera: Collaboration established in summer 2023 to increase global Ac-225 availability
- Ratio Therapeutics: June 2024 supply agreement for Ac-225 to support pipeline of targeted cancer medicines
Competitors are also moving aggressively:
- Niowave signed supply deals with both Novartis (2026) and AstraZeneca (10-year agreement in December 2025)
Clinical Applications and Pipeline Development
Actinium-225-based radiopharmaceuticals are in development for multiple cancer types, including:
- Leukemia
- Melanoma
- Prostate cancer
- Neuroendocrine tumors
While no Ac-225-based drugs have yet reached market approval, numerous candidates are advancing through clinical trials, driving demand for reliable isotope supply.
Key Takeaways:
- $450 million investment in 250,000 sq ft Philadelphia manufacturing facility by Bill Gates-backed TerraPower Isotopes
- 20-fold increase in Ac-225 production capacity when combined with Washington facility expansion
- Facility operational in 2029, creating 225 permanent jobs plus 500 construction positions
- Ac-225 is alpha-emitting radioisotope viewed as “next revolution” after lutetium-177 in radiopharmaceuticals
- Philadelphia selected after evaluating 350+ locations for life sciences ecosystem and infrastructure
- Pennsylvania investing $10 million in state grants and tax incentives
- TPI produces Ac-225 from legacy U.S. nuclear material using proprietary technology
- Positions TPI as premier global distributor amid severe supply shortage
- Strategic partnerships with PanTera, Ratio Therapeutics support pipeline development
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada